https://ashibio.com/ashibio-raises-40m-in-seed-and-series-a-financing-to-advance-therapies-for-bone-and-connective-tissue-disorders/ 2024-06-25T19:15:50+00:00 https://ashibio.com/wp-content/uploads/2024/06/ashibio-featureed-image.jpg https://ashibio.com/ashibio-announces-appointment-of-dipal-doshi-ceo-of-entrada-therapeutics-to-its-board-of-directors/ 2024-09-17T12:30:00+00:00 https://ashibio.com/wp-content/uploads/2024/06/ashibio-featureed-image.jpg https://ashibio.com/ashibio-doses-first-patient-in-andecal-study-a-phase-2-3-trial-of-andecaliximab-for-treatment-of-fibrodysplasia-ossificans-progressiva-fop/ 2025-01-23T13:30:00+00:00 https://ashibio.com/wp-content/uploads/2024/06/ashibio-featureed-image.jpg https://ashibio.com/ashibio-doses-first-patient-in-phase-1b-trial-of-andecaliximab-in-patients-with-spinal-cord-injury-sci-at-risk-of-heterotopic-ossification-ho/ 2025-06-24T12:30:00+00:00 https://ashibio.com/wp-content/uploads/2024/06/ashibio-featureed-image.jpg https://ashibio.com/ashibio-expands-clinical-pipeline-with-vantictumab-a-first-in-class-antibody-for-autosomal-dominant-osteopetrosis-type-2/ 2025-08-19T12:30:00+00:00 https://ashibio.com/wp-content/uploads/2024/06/ashibio-featureed-image.jpg https://ashibio.com/wp-content/uploads/2024/10/ASBMR_1374513-24_PosterDraft-latest-Copy-updated.pdf 2025-08-21T20:49:54+00:00 https://ashibio.com/wp-content/uploads/2024/10/ashibio-DDF-Poster-2024-FINAL.pdf 2025-08-21T20:52:55+00:00 https://ashibio.com/wp-content/uploads/2024/10/ICCBH-2024-poster.pdf 2025-08-21T20:59:31+00:00 https://ashibio.com/ashibio-reports-promising-preclinical-data-for-two-first-in-class-antibodies-targeting-debilitating-bone-disorders-at-asbmr-meeting/ 2025-09-08T12:30:00+00:00 https://ashibio.com/wp-content/uploads/2024/06/ashibio-featureed-image.jpg https://ashibio.com/wp-content/uploads/2025/09/ASBMR_VAN_poster-082525_final.pdf 2025-09-08T19:07:54+00:00 https://ashibio.com/wp-content/uploads/2025/09/ASBMR_2025-BT-20250730_draft_v1.pdf 2025-09-08T19:12:58+00:00